New deucrictibant HAE Phase 3 results show that an oral capsule taken at the start of a hereditary angioedema attack ended the progression of symptoms faster than placebo, with relief beginning in about 1.28 hours. Pharvaris announced on 8 October 2026 that the RAPIDe-3 study has been published in The Lancet, strengthening a filing that the FDA is already reviewing.
Hereditary angioedema, or HAE, causes sudden swelling of the skin, gut and airway that can be painful and sometimes dangerous. Patients want treatments that work quickly and can be carried and taken without an injection. This article explains what the study found, what the company has not disclosed, and where deucrictibant stands with regulators.
Deucrictibant HAE Phase 3 results: key points
- Study: RAPIDe-3, a global, randomised, double-blind, placebo-controlled crossover study in adolescents and adults with HAE attacks.
- Treatment: a single 20 mg oral immediate-release capsule taken for on-demand use.
- Speed: time to onset of symptom relief of 1.28 hours and time to complete symptom resolution of 11.95 hours, as reported.
- Endpoints: the primary endpoint and all 11 secondary endpoints were met, per Pharvaris.
- Regulatory: a US filing is under FDA review with an action date of 23 April 2027, and an EU application is under review.
What is deucrictibant in the HAE Phase 3 programme and how does it work?
Deucrictibant is an oral, small-molecule drug that blocks the bradykinin B2 receptor. In HAE, too much of a chemical messenger called bradykinin leaks fluid out of blood vessels and causes swelling. By blocking the receptor that bradykinin acts on, deucrictibant aims to stop the swelling whichever genetic or biological route led to the excess.
Pharvaris is developing two forms: an immediate-release capsule for on-demand treatment of attacks, tested in RAPIDe-3, and an extended-release tablet for prevention, tested in the CHAPTER-3 study. The FDA, the European Commission and Swissmedic have each granted orphan drug designation.
Inside the RAPIDe-3 deucrictibant HAE Phase 3 study
In a crossover design, each participant treats different attacks with either the drug or a placebo, so every patient acts as their own comparison. That helps with a condition like HAE, where attacks vary widely from person to person. The primary endpoint was the end of progression of attack symptoms, which deucrictibant reached significantly sooner than placebo.
- Single dose: most attacks were adequately controlled with one capsule.
- Consistency: results were similar across age, region, HAE type, use of long-term prevention, and attack severity and location.
- Subtypes: the benefit was seen in HAE with normal C1 inhibitor as well as in other types.
- Laryngeal attacks: non-severe attacks of the larynx were included in the consistency analysis.
The release does not give the number of participants or the matching placebo times for onset of relief and resolution, so we cannot say how large the speed advantage was. Readers should look for the full figures in the Lancet paper and on ClinicalTrials.gov.
Why the deucrictibant HAE Phase 3 data on faster oral treatment matter
Attacks can be unpredictable and last days if untreated. Current on-demand options include injections and, more recently, an oral drug that works by a different route, so a capsule that quickly halts swelling would add to patient choice. Patients often delay treatment because of the inconvenience of injecting, and a small oral dose could make earlier treatment easier.
Earlier-stage treatment tends to mean shorter attacks, but that is a general principle and not a finding from this release. The US Hereditary Angioedema Association provides patient information on living with the condition.
Beyond the deucrictibant HAE Phase 3 study: CHAPTER-3 prevention data
In a separate announcement on 8 September 2026, Pharvaris reported that the CHAPTER-3 study of the extended-release tablet met its primary endpoint, with an 83% reduction in attack rate compared with placebo. The company describes it as the first Phase 3 prevention study across all three types of HAE. We have not seen the full dataset, and one figure of 87% appears in a partial summary whose meaning is unclear, so we report only the 83%.
Together, the two programmes would let one company offer both on-demand and preventive oral therapy, which would be a notable position in a small, specialised market.
Regulatory timeline after the deucrictibant HAE Phase 3 results
- US: new drug application under FDA review, with a target action date of 23 April 2027.
- EU: marketing authorisation application under review by the European Medicines Agency.
- Access now: an expanded access programme is available to eligible US patients, according to the company.
- Earlier data: RAPIDe-1 results were published in April 2026 in The Lancet Haematology, and the RAPIDe-3 results are described as consistent.
An FDA action date is not a guarantee of approval. The agency can approve, ask for more information or decline. Our reports on a Phase 3 success in Parkinson’s disease and a new rare-disease start-up show how often small-patient-group drugs depend on regulatory timelines.
Safety and limits of the deucrictibant HAE Phase 3 data
Pharvaris says deucrictibant was well tolerated with no safety signals in RAPIDe-3, but the release gives no adverse-event rates. The study was conducted by the sponsor, and its claims, including the timing of relief, are drawn from the Pharvaris announcement. Independent review will matter, especially for longer-term safety in people who treat many attacks a year.
Our assessment of the deucrictibant HAE Phase 3 data
In our assessment, the deucrictibant HAE Phase 3 data are encouraging, mainly because they cover a range of HAE types and attack severities, and because they are now peer-reviewed. The open questions are the size of the benefit against placebo and how the drug compares with existing on-demand treatments, since no head-to-head study exists. If approved, its place will be decided by speed, convenience and price.
For more drug-development coverage, browse our pharmaceutical news section.
What to watch next after the deucrictibant HAE Phase 3 results
- The 23 April 2027 FDA decision.
- The European Medicines Agency’s opinion.
- Full CHAPTER-3 data on the preventive tablet.
- Real-world comparisons with other on-demand HAE treatments.
Frequently asked questions
What did the deucrictibant HAE Phase 3 study show?
It showed that a 20 mg oral capsule ended attack progression faster than placebo, with onset of relief at 1.28 hours and complete resolution at 11.95 hours.
Is deucrictibant approved after the HAE Phase 3 study?
Not yet. The FDA is reviewing it with a target action date of 23 April 2027.
What is HAE?
A rare condition in which too much bradykinin causes recurring episodes of swelling.
How is deucrictibant taken?
The on-demand form is an oral capsule taken at the start of an attack.
Is there a preventive version?
Yes, an extended-release tablet is being tested for prevention, and CHAPTER-3 showed an 83% reduction in attack rate.
How we reported this: we based this article on the Pharvaris announcement of 8 October 2026 and public trial and patient-group pages. Efficacy figures are the company’s and we have not read the full paper. Last updated: 12 October 2026. This article is news reporting and not medical advice.
